vs
STANDARD BIOTOOLS INC.（LAB）与Spok Holdings, Inc（SPOK）财务数据对比。点击上方公司名可切换其他公司
Spok Holdings, Inc的季度营收约是STANDARD BIOTOOLS INC.的1.7倍（$33.9M vs $19.6M），Spok Holdings, Inc净利率更高（8.7% vs -177.4%，领先186.1%），Spok Holdings, Inc同比增速更快（-0.1% vs -11.5%），Spok Holdings, Inc自由现金流更多（$10.1M vs $-23.1M），过去两年Spok Holdings, Inc的营收复合增速更高（-1.5% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Spok Holdings, Inc.是一家主要服务医疗健康行业的关键通信解决方案提供商，主打统一临床通信平台、安全消息工具、警报系统和值班调度软件，帮助医护团队高效协作，缩短响应时长，提升医疗机构的患者安全水平。
LAB vs SPOK — 直观对比
营收规模更大
SPOK
是对方的1.7倍
$19.6M
营收增速更快
SPOK
高出11.4%
-11.5%
净利率更高
SPOK
高出186.1%
-177.4%
自由现金流更多
SPOK
多$33.2M
$-23.1M
两年增速更快
SPOK
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $33.9M |
| 净利润 | $-34.7M | $2.9M |
| 毛利率 | 48.5% | 76.7% |
| 营业利润率 | -168.5% | 11.6% |
| 净利率 | -177.4% | 8.7% |
| 营收同比 | -11.5% | -0.1% |
| 净利润同比 | -28.8% | -19.6% |
| 每股收益（稀释后） | $-0.09 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSPOK
| Q4 25 | — | $33.9M | ||
| Q3 25 | $19.6M | $33.9M | ||
| Q2 25 | $21.8M | $35.7M | ||
| Q1 25 | $40.8M | $36.3M | ||
| Q4 24 | — | $33.9M | ||
| Q3 24 | $22.1M | $34.9M | ||
| Q2 24 | $22.5M | $34.0M | ||
| Q1 24 | $45.5M | $34.9M |
净利润LABSPOK
| Q4 25 | — | $2.9M | ||
| Q3 25 | $-34.7M | $3.2M | ||
| Q2 25 | $-33.5M | $4.6M | ||
| Q1 25 | $-26.0M | $5.2M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $-26.9M | $3.7M | ||
| Q2 24 | $-45.7M | $3.4M | ||
| Q1 24 | $-32.2M | $4.2M |
毛利率LABSPOK
| Q4 25 | — | 76.7% | ||
| Q3 25 | 48.5% | 78.3% | ||
| Q2 25 | 48.8% | 79.5% | ||
| Q1 25 | 48.4% | 80.1% | ||
| Q4 24 | — | 78.5% | ||
| Q3 24 | 54.9% | 79.5% | ||
| Q2 24 | 46.1% | 78.9% | ||
| Q1 24 | 53.1% | 79.5% |
营业利润率LABSPOK
| Q4 25 | — | 11.6% | ||
| Q3 25 | -168.5% | 12.9% | ||
| Q2 25 | -118.1% | 15.1% | ||
| Q1 25 | -80.8% | 16.6% | ||
| Q4 24 | — | 13.7% | ||
| Q3 24 | -120.9% | 14.2% | ||
| Q2 24 | -134.5% | 13.2% | ||
| Q1 24 | -132.2% | 14.0% |
净利率LABSPOK
| Q4 25 | — | 8.7% | ||
| Q3 25 | -177.4% | 9.5% | ||
| Q2 25 | -153.7% | 12.8% | ||
| Q1 25 | -63.8% | 14.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | -122.0% | 10.5% | ||
| Q2 24 | -203.3% | 10.1% | ||
| Q1 24 | -70.6% | 12.1% |
每股收益（稀释后）LABSPOK
| Q4 25 | — | $0.13 | ||
| Q3 25 | $-0.09 | $0.15 | ||
| Q2 25 | $-0.09 | $0.22 | ||
| Q1 25 | $-0.07 | $0.25 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | $-0.07 | $0.18 | ||
| Q2 24 | $-0.12 | $0.17 | ||
| Q1 24 | $-0.27 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $25.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $146.4M |
| 总资产 | $539.6M | $206.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSPOK
| Q4 25 | — | $25.3M | ||
| Q3 25 | $129.4M | $21.4M | ||
| Q2 25 | $158.6M | $20.2M | ||
| Q1 25 | $150.9M | $19.9M | ||
| Q4 24 | — | $29.1M | ||
| Q3 24 | $210.6M | $27.8M | ||
| Q2 24 | $269.8M | $23.9M | ||
| Q1 24 | $287.1M | $23.3M |
总债务LABSPOK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSPOK
| Q4 25 | — | $146.4M | ||
| Q3 25 | $399.7M | $148.7M | ||
| Q2 25 | $424.5M | $150.9M | ||
| Q1 25 | $454.6M | $151.7M | ||
| Q4 24 | — | $154.7M | ||
| Q3 24 | $489.3M | $156.3M | ||
| Q2 24 | $510.3M | $158.2M | ||
| Q1 24 | $577.3M | $160.2M |
总资产LABSPOK
| Q4 25 | — | $206.1M | ||
| Q3 25 | $539.6M | $209.7M | ||
| Q2 25 | $557.0M | $208.7M | ||
| Q1 25 | $579.6M | $204.5M | ||
| Q4 24 | — | $217.1M | ||
| Q3 24 | $681.5M | $216.8M | ||
| Q2 24 | $708.7M | $216.4M | ||
| Q1 24 | $777.7M | $215.0M |
负债/权益比LABSPOK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $11.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $10.1M |
| 自由现金流率自由现金流/营收 | -118.1% | 29.9% |
| 资本支出强度资本支出/营收 | 4.5% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 3.93× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $25.2M |
8季度趋势，按日历期对齐
经营现金流LABSPOK
| Q4 25 | — | $11.5M | ||
| Q3 25 | $-22.2M | $8.1M | ||
| Q2 25 | $-20.7M | $7.0M | ||
| Q1 25 | $-30.3M | $2.3M | ||
| Q4 24 | — | $8.4M | ||
| Q3 24 | $-27.9M | $11.1M | ||
| Q2 24 | $-39.0M | $7.4M | ||
| Q1 24 | $-62.5M | $2.0M |
自由现金流LABSPOK
| Q4 25 | — | $10.1M | ||
| Q3 25 | $-23.1M | $7.6M | ||
| Q2 25 | $-22.6M | $6.0M | ||
| Q1 25 | $-35.3M | $1.5M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | $-30.1M | $10.3M | ||
| Q2 24 | $-41.0M | $6.8M | ||
| Q1 24 | $-63.3M | $1.1M |
自由现金流率LABSPOK
| Q4 25 | — | 29.9% | ||
| Q3 25 | -118.1% | 22.4% | ||
| Q2 25 | -103.6% | 16.8% | ||
| Q1 25 | -86.6% | 4.2% | ||
| Q4 24 | — | 22.3% | ||
| Q3 24 | -136.4% | 29.4% | ||
| Q2 24 | -182.2% | 20.0% | ||
| Q1 24 | -138.9% | 3.2% |
资本支出强度LABSPOK
| Q4 25 | — | 4.1% | ||
| Q3 25 | 4.5% | 1.6% | ||
| Q2 25 | 8.7% | 2.9% | ||
| Q1 25 | 12.4% | 2.1% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 10.2% | 2.4% | ||
| Q2 24 | 8.6% | 1.9% | ||
| Q1 24 | 1.7% | 2.5% |
现金转化率LABSPOK
| Q4 25 | — | 3.93× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 3.03× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 0.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SPOK
| Paging | $16.8M | 50% |
| Software Operations | $16.0M | 47% |
| License | $1.2M | 4% |
